Kaomi ma aneʻi e hōʻike i kāu mau hae ma kēia ʻaoʻao a uku wale no ka holomua

Nuhou Uea

Ua loaʻa i ka mākeke lāʻau lapaʻau Marijuana he $76.5 biliona e 2031

i kakauia ma hoʻoponopono

Wahi a kahi noiʻi hou e Persistence Market Research, ke manaʻo nei ka mākeke olakino olakino e ʻike i ka ulu kiʻekiʻe ma kahi CAGR ma kahi o 14.8% a hiki i kahi kumukūʻai o US $ 76.5 Bn e 2031.

Hoʻokumu ʻia ka marijuana lāʻau mai ka lāʻau Cannabis sativa. ʻO nā pūhui ikaika nui ʻekolu o ka mea kanu he tetrahydrocannabinol, cannabidiol, a me cannabinol. He mau noi like ʻole ka lāʻau lapaʻau i ka mālama olakino a me ka lapaʻau lapaʻau, me ka mālama ʻana a i ʻole ka mālama ʻana i ka ʻeha, ka mālama ʻana i ka nausea, nā ʻiʻo spasms, ka mālama ʻana i ka hopohopo, ka sclerosis lehulehu, ka haʻahaʻa haʻahaʻa, nā pilikia hiamoe, a me nā mea he nui.

ʻO nā kumu ʻē aʻe e koi ai i ka lāʻau lapaʻau e pili ana i ka hiki ke mālama a mālama i ka insomnia a me ka epilepsy. Wahi a ka poʻe loea mālama ola kino, he koho kūpono ka lāʻau lapaʻau no ka hoʻoponopono ʻana i nā pilikia pili i ka hiamoe no ka mea e hoʻihoʻi ia i ke kaʻina hiamoe kūlohelohe o ke kanaka e loli ana ma muli o ke ʻano o kēia mau lā.

ʻIke ʻia ʻo marijuana lāʻau no kāna mau waiwai anti-inflammatory ikaika. Hiki iā ia ke mālama i ka ʻāʻī mai ka maʻi arthritis a me nā loli degenerative i loko o ka lumbar, cervical or thoracic spine. Nui nā poʻe maʻi e hoʻohana i ka marijuana e mālama i ko lākou ʻeha i hana ʻia ma muli o ka mumū.

Hoʻokumu ʻia nā hui lāʻau lapaʻau i ka loaʻa ʻana o nā ʻae mai nā luna aupuni ʻē aʻe no ka hoʻohana ʻana i ka lāʻau lapaʻau no nā kumu lapaʻau.

• I Kepakemapa 2019, ua ʻae ʻia ʻo GW Pharmaceuticals mai ʻEulopa i ke Komisina no EPIDYOLEX® (cannabidiol) no ka mālama ʻana i ka hopu ʻana i nā mea maʻi me ʻelua mau ʻano koʻikoʻi o ka wā kamaliʻi.

• I ʻOkakopa 2021, ua hoʻolaha ʻo Canopy Growth Corporation i kahi hoʻolālā e loaʻa iā Wana Entity, ʻo ia ka inoa o ka cannabis edibles kaulana ma ʻAmelika ʻĀkau.

• Ma ʻAukake 2020, hoʻolaha ʻo MedReleaf Corp. a me BioPharma Services Inc. i kā lākou ʻaelike e hana i ka noiʻi lapaʻau no ka cannabis a me nā huahana i loaʻa mai i ka cannabis.

Nā Takeaways Key mai ka Mākeke Study

• Hoʻohana nui ʻia ke ʻano extract o ka marijuana ma nā ʻano hana like ʻole i ka māla lapaʻau e like me nā pua maloʻo.

• Ua hauʻoli ka ʻāpana hoʻokele ʻeha i ka māhele mākeke kiʻekiʻe o 48.8%, e hōʻike ana i ke koi kiʻekiʻe no ka lāʻau lapaʻau i nā kaʻina hana hoʻomalu ʻeha.

• 77.6% ka māhele o ka mākeke ma ka māhele o ke kahawai hoʻolaha e mālama ʻia e nā hale kūʻai kūʻai, no ka mea, ua hoʻoponopono ʻia ka mākeke e nā luna aupuni.

• Hoʻomaka ka mākeke ʻAmelika ʻĀkau e ulu 5X e 2031.

"ʻO ka hoʻonui nui ʻana o ka ʻeha maʻi a me ka epilepsy a me ka legalization o ka lāʻau lapaʻau i nā ʻāina e ulu nei nā kumu nui e koi ai," wahi a kahi mea noiʻi ʻo Persistence Market Research.

ʻO wai ka Lanakila?

Ke hana mau nei nā mea hana lāʻau lapaʻau lāʻau i ka hoʻonui ʻana i kā lākou huahana portfolios a me ka hele ʻana o ka mākeke ma o nā hoʻolālā koʻikoʻi e like me ka ʻae ʻana o ka huahana a me ka hāʻawi ʻana a me nā ʻaelike hui.

• Ua loaʻa iā GW Pharmaceuticals ka ʻae ʻia mai Australian Therapeutic Goods Administration (TGA) no EPIDYOLEX® (cannabidiol) no ka maʻi epilepsy (2020). Ua ʻae ka FDA i ka hopena waha ʻo EPIDIOLEX® (cannabidiol) no ka mālama ʻana i nā maʻi e pili ana i ka paʻakikī o ka tuberous sclerosis.

• Ua pūlima ʻo Tilray i kahi ʻaelike hoʻolaha me nā mea hoʻolaha ʻākau nui no nā kūʻai cannabis hoʻohana kanaka makua ma Kanada.

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

Kaʻana like i...